Reboxetine

Generic Name
Reboxetine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H23NO3
CAS Number
71620-89-8
Unique Ingredient Identifier
947S0YZ36I
Background

Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.

Indication

For the treatment of clinical depression.

Associated Conditions
Major Depressive Disorder (MDD)
Associated Therapies
Maintenances
Clinical Trials
Related News

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

First Posted Date
2021-11-24
Last Posted Date
2024-08-19
Lead Sponsor
University of Haifa
Target Recruit Count
53
Registration Number
NCT05133804
Locations
🇮🇱

University of Haifa, Haifa, Israel

🇮🇱

Lev HaSharon Mental Health Center, Netanya, Israel

🇮🇱

Emek Medical Center, Afula, Israel

Studying the Role of Brain Molecules for Decision Making

First Posted Date
2020-05-12
Last Posted Date
2024-05-08
Lead Sponsor
University of Zurich
Target Recruit Count
160
Registration Number
NCT04384562
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Reboxetine
Drug: Placebos
Drug: Methylphenidate
First Posted Date
2020-05-01
Last Posted Date
2020-05-01
Lead Sponsor
University of Zurich
Target Recruit Count
120
Registration Number
NCT04371146
Locations
🇨🇭

University of Zurich, Zurich, Switzerland

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Not Applicable
Completed
Conditions
Healthy
Interventions
Drug: Placebo oral tablet
Drug: Rivastigmine
Drug: Reboxetine
First Posted Date
2019-05-21
Last Posted Date
2020-06-16
Lead Sponsor
University of Oxford
Target Recruit Count
107
Registration Number
NCT03957174
Locations
🇬🇧

Dept of Psychiatry, University of Oxford, Oxford, Oxfordshire, United Kingdom

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Antidepressants and Bone Mineral Density

First Posted Date
2014-07-01
Last Posted Date
2014-07-01
Lead Sponsor
Guiyang Medical University
Target Recruit Count
203
Registration Number
NCT02179268

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

First Posted Date
2011-02-21
Last Posted Date
2011-02-21
Lead Sponsor
Fundació Sant Joan de Déu
Target Recruit Count
249
Registration Number
NCT01300364
Locations
🇪🇸

Parc Sanitari Sant Joan de Déu, Sant Boi Llobregat, Barcelona, Spain

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

First Posted Date
2009-10-14
Last Posted Date
2009-10-14
Lead Sponsor
Zentrum für Integrative Psychiatrie
Target Recruit Count
45
Registration Number
NCT00993876
Locations
🇩🇪

Zentrum für Integrative Psychiatrie, Kiel, Germany

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

First Posted Date
2009-03-02
Last Posted Date
2024-12-10
Lead Sponsor
Universitätsklinikum Hamburg-Eppendorf
Target Recruit Count
12
Registration Number
NCT00853866
Locations
🇩🇪

University Hospital Hamburg-Eppendorf, Department of Neurology, Hamburg, HH, Germany

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Phase 4
Conditions
Depression
First Posted Date
2007-01-25
Last Posted Date
2007-01-25
Lead Sponsor
Geha Mental Health Center
Target Recruit Count
60
Registration Number
NCT00426946
Locations
🇮🇱

Tel Aviv Community Mental Helath Center, Tel Aviv, Israel

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy